Latest Commercialization News

Linius Technologies reported a $5.31 million loss for FY25 as it shifts towards a sales-driven SaaS model, with new leadership and cost-cutting measures aiming to reshape its future.

Qualitas Real Estate Income Fund (QRI) has declared a distribution for August 2025, delivering an annualised yield of 6.32% based on its net tangible assets. The fund continues to focus on mortgage-backed real estate loans across Australia, aiming to provide steady income and capital preservation.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

Macarthur Minerals Limited reported a successful capital raise and key strategic partnerships at its 2025 AGM, positioning itself for future growth in iron ore production.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.

First Graphene Limited reported a 13% reduction in net loss for FY25 alongside steady revenue and expanding commercial demand for its PureGRAPH products.

SportsHero Limited reported a 189% revenue increase to AU$37,666 for FY25, driven by strategic partnerships across Southeast Asia, despite a continuing loss of nearly AU$2 million. The company secured major telco collaborations and expanded its gaming product footprint in Indonesia and the Philippines.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.